The physical symptoms that people experience during an intravenous nicotinamide adenine dinucleotide (NAD+) infusion include abdominal cramping, nausea, flushing, chest pressure, and an increased heart rate. These reactions are frequent enough that in the only published clinical chart review evaluating intravenous protocols, every single client receiving intravenous NAD+ experienced moderate to severe symptoms. Administering clinicians typically manage these episodes by slowing the infusion rate rather than abandoning the procedure.
At Longevity Benchmark, in the guides we publish here, the reactions people describe during a NAD+ infusion are among the most searched and least documented parts of this topic. A person evaluating parenteral therapy must separate the direct pharmacological effects of the molecule from the quality risks introduced during compounding. Those evaluating oral regimens should read our companion review of NMN side effects for non-injectable tolerability profiles.
The published clinical record for injectable NAD+ rests on a small number of preliminary human studies. The delivery routes, what the infusion itself involves, and why no trial has established a schedule are covered in our guide to NAD injections.
The Verdict
Intravenous NAD+ infusions regularly cause uncomfortable physical reactions, including abdominal cramping, nausea, flushing, and chest pressure, which appear directly tied to how fast the fluid is delivered. In the published commercial clinic series, every single patient receiving intravenous NAD+ experienced these moderate to severe reactions, whereas participants in a slower 6-hour controlled trial experienced no adverse events.
Beyond transient infusion distress, compounded injectable vials carry real contamination hazards, demonstrated by 14 federal recall actions for sterility failures and elevated endotoxins.
Acute Symptoms Reported During Intravenous Infusions
The physical reactions individuals report during an intravenous NAD+ infusion include abdominal cramping, nausea, flushing, chest pressure, and an increased heart rate. These adverse events are so common that in the only published clinic series comparing intravenous protocols, every single NAD+ patient experienced them. Clinicians typically manage these symptoms by slowing the drip rate rather than stopping the infusion.
Gastrointestinal distress is the most frequent acute complaint documented during active administration. Clients describe sudden mid-abdominal cramping, waves of nausea, intestinal urgency, diarrhoea, and occasional vomiting. These digestive sensations begin within minutes of opening the intravenous line and persist if fluid delivery remains rapid.
Upper-body vascular and respiratory sensations frequently accompany the digestive distress. Individuals report localized tightness or heaviness in the chest, a racing heart rate, diffuse cutaneous flushing, throat soreness, and sinus congestion. These sensations reflect acute systemic responses to the circulating compound rather than the underlying cellular mechanisms detailed in our guide on what NAD+ does.
These physical reactions are transient and typically diminish once the infusion stops or the flow slows to a lower drip velocity. Once the session ends and the compound clears the vascular compartment, participants in short-term studies report that active cramping and nausea subside quickly.
Evidence from the Published Clinic Tolerability Series
The primary comparative tolerability record for intravenous NAD+ comes from a retrospective electronic-medical-record review conducted in a commercial wellness clinic.
A retrospective tolerability pilot evaluated client records comparing intravenous NAD+ against intravenous nicotinamide riboside (NR). The cohort comprised 14 total subjects: 6 received intravenous NAD+ and 8 received intravenous NR. Both groups received 500 mg of active compound diluted in 500 mL of 0.9% normal saline on four continuous days at the same scheduled time each day.
The delivery times between the two compounds diverged sharply. The mean infusion duration was 97 ± 56.33 minutes for the NAD+ group, compared to 37 ± 13.08 minutes for the NR group. That represents a 60% reduction in delivery duration for NR.
Tolerability outcomes differed across the cohorts. All six clients receiving NAD+ experienced moderate to severe abdominal cramping, diarrhoea, nausea, vomiting, increased heart rate, throat pain, congestion, and chest pressure during their sessions. By contrast, five of the eight NR recipients reported minor tingling in the tongue, jaw, and arms alongside minor cramping. One NR patient experienced severe cramping that coincided with menstruation.
The authors concluded that NR infusions were delivered more rapidly with minor adverse events compared with NAD+. They noted that both treatments appeared well tolerated regarding systemic blood markers. However, the study carries severe methodological limitations: it was a retrospective chart review, the cohort of 14 people was tiny, there was no placebo-controlled arm, and the trial was designed and executed by a commercial clinic entity, which introduced potential implicit bias.
Infusion Velocity and the Controlled Pharmacokinetic Study
Slowing the delivery rate of an intravenous NAD+ infusion appears to eliminate the acute adverse reactions observed during rapid administration.
A controlled pharmacokinetic pilot study evaluated plasma and urine metabolites during a constant intravenous infusion in 11 male participants aged 30 to 55. Eight participants received 750 mg of NAD+ diluted in normal saline over an extended 6-hour period, while three control participants received normal saline alone.
The infusion rate was set at roughly 2 mg per minute, equivalent to 3 micromoles per minute. Under these controlled parameters, the researchers observed zero adverse events during the entire 6-hour session.
The contrast between these two investigations is striking. In the clinic series, a smaller 500 mg dose infused over roughly 97 minutes caused moderate to severe distress in every patient. In the pharmacokinetic study, a larger 750 mg dose infused over 360 minutes caused no distress at all.
This difference suggests that infusion velocity, rather than total dose, triggers acute gastrointestinal and circulatory side effects. However, this comparison involves two small trials with different participant demographics and administration settings. The rate-dependent tolerability link remains an interesting clinical observation rather than a proven physiological mechanism. Readers considering non-drip methods can examine our analysis of transdermal NAD patches.
Biomarker Stability Across Liver Enzymes and Inflammatory Markers
Short-term intravenous infusions of NAD+ have not caused clinically detectable hepatic injury or elevations in systemic inflammation in published human cohorts.
In the retrospective clinic review, clinicians obtained comprehensive blood panels before and after the 4-day infusion series. Neither the 6 clients receiving NAD+ nor the 8 clients receiving NR showed clinically significant changes in circulating liver enzymes or systemic inflammatory markers. The authors interpreted these findings as preliminary evidence of short-term hepatic safety at a 500 mg daily exposure level.
Stable blood markers over four days provide reassuring acute data, but they do not prove long-term organ safety. Monitoring liver function remains standard practice in physician-supervised protocols. Readers comparing clinical pricing structures can review our breakdown of longevity clinic cost and diagnostic programs.
Product Quality and Sterile Compounding Contamination Risks
Contamination risks arising from unregulated compounding pharmacy practices represent a serious danger distinct from the direct physical side effects of the NAD+ molecule.
Because injectable NAD+ lacks regulatory drug approval from the Food and Drug Administration (FDA) for anti-aging applications, clinics and telehealth providers source their vials from custom compounding pharmacies. Quality control across these facilities varies widely.
A query of the FDA enforcement report database conducted on 27 September 2026 revealed 14 recall records involving injectable nicotinamide adenine dinucleotide products between 2016 and 2025 across 7 distinct compounding firms. Thirteen actions were categorized as Class II recalls, and one action was categorized as a Class I recall, representing situations where exposure carries a reasonable probability of serious health consequences or death.
Ten of the 14 recalls were triggered by a lack of sterility assurance or microbial contamination. The Class I recall involved GenoGenix LLC for NAD+ for Injection in 100 mg/mL and 200 mg/mL potencies across 10 mL multi-dose amber vials. The recall was initiated on 30 July 2025 and reported on 15 October 2025 due to microbial contamination of sterile products and elevated endotoxin levels.
Endotoxin exposure during an injection or infusion can trigger severe pyrogenic reactions, including high fevers, systemic inflammatory shock, and rapid drops in blood pressure. A patient who develops sudden fever or chills cannot assume the reaction is a normal infusion flush. Anyone experiencing persistent or worsening symptoms after leaving an injection appointment should contact a licensed medical clinician immediately.
Clinical Evidentiary Gaps and Safety Boundaries
The medical literature contains no long-term safety data, no large placebo-controlled adverse event registries, and no pharmacokinetic data in pregnant populations for injectable NAD+.
The published human evidence base consists solely of small exploratory pilots and retrospective commercial charts. Researchers have not tested injectable NAD+ in randomised controlled trials powered to detect rare cardiovascular, neurological, or immunological events. Furthermore, no studies have investigated how high-dose parenteral NAD+ interacts with prescription pharmaceuticals.
Intravenous and intramuscular NAD+ have not been studied in pregnancy or breastfeeding, and the acute heart-rate and chest-pressure reactions documented in the clinic series have never been evaluated in people with unstable cardiovascular disease. Patients who want to avoid compounding risks or acute physical reactions should evaluate non-parenteral alternatives in our comparison of NMN and NR or browse broader options in our guide to longevity supplements.
Our perspective on injectable tolerability would change if independent research groups publish prospective, placebo-controlled trials tracking adverse events across standardized infusion rates, accompanied by rigorous third-party batch testing of sterile preparations. Until those trials exist, patients must weigh unproven benefits against consistent acute discomfort and documentable sterility hazards.
Frequently Asked Questions
What are the side effects of NAD injections?
The most common side effects reported during NAD+ infusions are abdominal cramping, nausea, vomiting, diarrhoea, flushing, chest pressure, an elevated heart rate, and throat tightness. In a published retrospective study of clinical clients receiving 500 mg of intravenous NAD+, all six participants experienced moderate to severe symptoms during administration. These reactions usually start shortly after the infusion begins and diminish once the fluid flow stops. In addition to these physical reactions, compounded injectable products carry risks of microbial contamination and elevated endotoxin levels.
Why do NAD IV drips cause cramping and nausea?
Rapid delivery of NAD+ into the bloodstream triggers acute physiological responses in smooth muscle and vascular tissue. Although the precise cellular mechanism remains unproven, researchers suspect that high circulating concentrations stimulate autonomic nervous system responses and intestinal motility, leading to cramping, nausea, and changes in vascular tone. These reactions occur during fast delivery and were entirely absent in a study where researchers delivered a larger dose slowly over six hours. The acute symptoms reflect the speed of administration rather than long-term tissue toxicity.
Does slowing the infusion reduce NAD side effects?
Clinical evidence indicates that slowing the rate of infusion substantially reduces or eliminates adverse reactions. In a controlled pharmacokinetic study where 11 men received 750 mg of NAD+ at a slow rate of approximately 2 mg per minute over six hours, zero adverse events occurred. Conversely, in a commercial clinic series where 500 mg was infused over an average of 97 minutes, every participant suffered moderate to severe physical reactions. Clinicians routinely manage patient discomfort by reducing the drip velocity rather than discontinuing the session.
Are NAD injections safe?
There is insufficient scientific evidence to label NAD+ injections definitively safe or unsafe. Small pilot studies show that short-term infusions do not cause acute changes in liver enzymes or inflammatory markers, but no large, placebo-controlled trials have established long-term safety. Furthermore, because these products are produced by compounding pharmacies rather than approved through standard regulatory drug pathways, patients face quality risks. Federal regulators have issued 14 recalls for injectable NAD+ products, primarily for lack of sterility assurance.
Do NAD injections affect the liver?
Published human data has not shown adverse effects on liver enzymes following short-term intravenous administration. In the published retrospective clinic study, patients received 500 mg daily infusions of either NAD+ or nicotinamide riboside for four consecutive days without experiencing clinically significant changes in liver function tests or systemic inflammation markers. However, these data reflect only four days of treatment in a small group of 14 people. Long-term surveillance data on hepatic function with repeated injections does not exist.
What are the long-term side effects of NAD injections?
The long-term side effects of repeated NAD+ injections and infusions remain completely unknown because no multi-month or multi-year clinical trials have evaluated the practice. Published studies have tracked patients for only a few days or weeks, focusing on immediate pharmacokinetics rather than chronic toxicity. Potential concerns regarding repeated compounding exposure, metabolic pathway saturation, or vascular stress have not been studied systematically in human cohorts. Anyone undertaking ongoing therapy does so without the backing of long-term safety data.
Who should avoid NAD injections?
No safety data exists for injectable NAD+ in pregnancy or breastfeeding, and none exists for people with active liver disease or unstable cardiovascular conditions. That absence is why clinicians do not offer the therapy to those groups, rather than a finding about risk. Anyone in one of them, or with a history of severe allergic reactions, needs that conversation with their own physician before an appointment is booked, alongside the question of where the clinic sources its compounded product.